Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Duncan R. Polymer therapeutics: Top 10 selling pharmaceuticals – what next? J. Control. Release 190(0), 371–380 (2014).
  Medline CASGoogle Scholar
• 2 Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 8(6), 2101–2141 (2011).
  Medline CASGoogle Scholar
• 3 Mochida Y, Cabral H, Miura Y et al. Bundled assembly of helical nanostructures in polymeric micelles loaded with platinum drugs enhancing therapeutic efficiency against pancreatic tumor. ACS Nano 8(7), 6724–6738 (2014).
  Medline CASGoogle Scholar
• 4 Nakamura H, Etrych T, Chytil P et al. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. J. Control. Release 174, 81–87 (2014).
  Medline CASGoogle Scholar
• 5 Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99(3), 392–397 (2008).
  Medline CASGoogle Scholar
• 6 Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 161(2), 175–187 (2012).
  Medline CASGoogle Scholar
• 7 Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387–6392 (1986).
  Medline CASGoogle Scholar
• 8 Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nano 7(12), 779–786 (2012).
  Medline CASGoogle Scholar
• 9 Hucknall A, Rangarajan S, Chilkoti A. In pursuit of zero: Polymer brushes that resist the adsorption of proteins. Adv. Mater. 21(23), 2441–2446 (2009).
  CASGoogle Scholar
• 10 Ostuni E, Chapman RG, Holmlin RE, Takayama S, Whitesides GM. A survey of structure−property relationships of surfaces that resist the adsorption of protein. Langmuir 17(18), 5605–5620 (2001).
  CASGoogle Scholar
• 11 Wei Q, Becherer T, Angioletti-Uberti S et al. Protein interactions with polymer coatings and biomaterials. Angew. Chem. Int. Ed. Engl. 53(31), 8004–8031 (2014).
  Medline CASGoogle Scholar
• 12 Tenzer S, Docter D, Kuharev J et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772–781 (2013).
  Medline CASGoogle Scholar
• 13 Tenzer S, Docter D, Rosfa S et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5(9), 7155–7167 (2011).
  Medline CASGoogle Scholar
• 14 Alexandridis P, Holzwarth JF, Hatton TA. Micellization of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymers in aqueous solutions: thermodynamics of copolymer association. Macromolecules 27(9), 2414–2425 (1994).
  CASGoogle Scholar
• 15 Mohr K, Sommer M, Baier G et al. Aggregation behavior of polystyrene-nanoparticles in human blood serum and its impact on the in vivo distribution in mice. J. Nanomed. Nanotechnol. 5(2), 1–10 (2014).
  Google Scholar
• 16 Birke A, Huesmann D, Kelsch A et al. Polypeptoid-block-polypeptide copolymers: synthesis, characterization, and application of amphiphilic block copolypept(o)ides in drug formulations and miniemulsion techniques. Biomacromolecules 15(2), 548–557 (2014).
  Medline CASGoogle Scholar
• 17 Heller P, Birke A, Huesmann D et al. Introducing peptoplexes: polylysine-block-polysarcosine based polyplexes for transfection of hek 293T cells. Macromol. Biosci. 14(10), 1380–1395 (2014).
  Medline CASGoogle Scholar
• 18 Luxenhofer R, Fetsch C, Grossmann A. Polypeptoids: a perfect match for molecular definition and macromolecular engineering? J. Polymer Sci. A 51(13), 2731–2752 (2013).
  CASGoogle Scholar
• 19 Luxenhofer R, Han Y, Schulz A et al. Poly(2-oxazoline)s as polymer therapeutics. Macromol. Rapid Commun. 33(19), 1613–1631 (2012).
  Medline CASGoogle Scholar
• 20 Viegas TX, Bentley MD, Harris JM et al. Polyoxazoline: chemistry, properties, and applications in drug delivery. Bioconjug. Chem. 22(5), 976–986 (2011).
  Medline CASGoogle Scholar
• 21 Barz M, Luxenhofer R, Zentel R, Vicent MJ. Overcoming the peg-addiction: well-defined alternatives to peg, from structure-property relationships to better defined therapeutics. Polymer Chemistry 2(9), 1900–1918 (2011).
  CASGoogle Scholar
• 22 Hemmelmann M, Mohr K, Fischer K, Zentel R, Schmidt M. Interaction of phpma-plma copolymers with human blood serum and its components. Mol. Pharm. 10(10), 3769–3775 (2013).
  Medline CASGoogle Scholar
• 23 Nuhn L, Gietzen S, Mohr K et al. Aggregation behavior of cationic nanohydrogel particles in human blood serum. Biomacromolecules 15(4), 1526–1533 (2014).
  Medline CASGoogle Scholar
• 24 Fang J, Nakamura H, Maeda H. The epr effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63(3), 136–151 (2011).
  Medline CASGoogle Scholar
• 25 Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int. J. Nanomedicine 9, 4357–4373 (2014).
  Medline CASGoogle Scholar
• 26 Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61(13), 1203–1213 (2009).
  Medline CASGoogle Scholar
• 27 Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280(5361), 243–248 (1998).
  Medline CASGoogle Scholar
• 28 Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112(1), 26–34 (2006).
  Medline CASGoogle Scholar
• 29 Reddy ST, Van Der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotech. 25(10), 1159–1164 (2007).
  Medline CASGoogle Scholar
• 30 Toth I, Skwarczynski M. The immune system likes nanotechnology. Nanomedicine (Lond.) 9(17), 2607–2609 (2014). •• Foreword of a special focus issue in Nanomedicine (Lond.) with highlights, reviews and research articles about ‘nanotechnology for vaccine development’.
  CASGoogle Scholar
• 31 Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunotherapy for cancer. ACS Nano 9(1), 16–30 (2015).
  Medline CASGoogle Scholar
• 32 Nuhn L, Barz M, Zentel R. New perspectives of HPMA-based copolymers derived by post-polymerization modification. Macromol. Biosci. 14(5), 607–618 (2014).
  Medline CASGoogle Scholar
• 33 Nuhn L, Hartmann S, Palitzsch B et al. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines. Angew. Chem. Int. Ed. Engl. 52(40), 10652–10656 (2013). •• First article describing novel glycopeptide polymer conjugates as antitumor vaccines for the co-delivery of tumor-associated MUC1 glycopeptide antigens together with a T-helper-cell epitope.
  Medline CASGoogle Scholar
• 34 Glaffig M, Palitzsch B, Hartmann S et al. A fully synthetic glycopeptide antitumor vaccine based on multiple antigen presentation on a hyperbranched polymer. Chemistry 20(15), 4232–4236 (2014).
  Medline CASGoogle Scholar
• 35 Cai H, Chen MS, Sun ZY, Zhao YF, Kunz H, Li YM. Self-adjuvanting synthetic antitumor vaccines from muc1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid. Angew. Chem. Int. Ed. Engl. 52(23), 6106–6110 (2013).
  Medline CASGoogle Scholar
• 36 Nuhn L. Enhancing gene knockdown efficiencies by comparing siRNA-loaded cationic nanogel particles of different sizes. RNA Dis. 2(1), e469 (2015).
  Google Scholar
• 37 Nuhn L, Hirsch M, Krieg B et al. Cationic nanohydrogel particles as potential sirna carriers for cellular delivery. ACS Nano 6(3), 2198–2214 (2012).
  Medline CASGoogle Scholar
• 38 Nuhn L, Tomcin S, Miyata K et al. Size-dependent knockdown potential of siRNA-loaded cationic nanohydrogel particles. Biomacromolecules 15(11), 4111–4121 (2014).
  Medline CASGoogle Scholar
• 39 Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471–484 (2006).
  Medline CASGoogle Scholar
• 40 Hartmann S, Nuhn L, Palitzsch B et al. CpG-loaded multifunctional cationic nanohydrogel particles as self-adjuvanting glycopeptide antitumor vaccines. Adv. Healthc. Mater. 4(4), 522–527 (2015). •• First article using glycopeptide nanogel conjugates as antitumor vaccines for co-delivery of tumor-associated MUC1 glycopeptide antigens together with immunostimulatory CpG.
  Medline CASGoogle Scholar
• 41 Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat. Rev. Drug Discov. 9(4), 308–324 (2010).
  Medline CASGoogle Scholar
• 42 Indications for Prevnar 13^®. www.adult.prevnar13.com
  Google Scholar
• 43 Bhatia S, Dimde M, Haag R. Multivalent glycoconjugates as vaccines and potential drug candidates. Med. Chem. Comm. 5(7), 862–878 (2014).
  CASGoogle Scholar
• 44 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909–915 (2004).
  Medline CASGoogle Scholar
• 45 Joffre O, Nolte MA, Sporri R, Reis E Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol. Rev. 227(1), 234–247 (2009).
  Medline CASGoogle Scholar
• 46 De Geest BG, Willart MA, Hammad H et al. Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. ACS Nano 6(3), 2136–2149 (2012).
  Medline CASGoogle Scholar
• 47 De Geest BG, Willart MA, Lambrecht BN et al. Surface-engineered polyelectrolyte multilayer capsules: synthetic vaccines mimicking microbial structure and function. Angew. Chem. Int. Ed. Engl. 51(16), 3862–3866 (2012).
  Medline CASGoogle Scholar
• 48 Den Haan JMM, Lehar SM, Bevan MJ. CD8(⁺) but not CD8(⁻) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med. 192(12), 1685–1696 (2000).
  Medline CASGoogle Scholar
• 49 Mintern JD, Percival C, Kamphuis MM, Chin WJ, Caruso F, Johnston AP. Targeting dendritic cells: the role of specific receptors in the internalization of polymer capsules. Adv. Healthc. Mater. 2(7), 940–944 (2013).
  Medline CASGoogle Scholar
• 50 Tappertzhofen K, Metz VV, Hubo M et al. Synthesis of maleimide-functionalyzed hpma-copolymers and in vitro characterization of the arage- and human immunoglobulin (huigg)–polymer conjugates. Macromol. Biosci. 13(2), 203–214 (2013).
  Medline CASGoogle Scholar
• 51 Tappertzhofen K, Bednarczyk M, Koynov K, Bros M, Grabbe S, Zentel R. Toward anticancer immunotherapeutics: well-defined polymer-antibody conjugates for selective dendritic cell targeting. Macromol. Biosci. 14(10), 1444–1457 (2014). •• Article showing selective uptake of multifunctional HPMA polymer systems into CD8+ dendritic cells via anti-DEC205 antibodies in the presence of phagocyting macrophages.
  Medline CASGoogle Scholar
• 52 Nuhn L. Addressing dendritic cells for anticancer immunity. J. Antibody Drug Conjug. doi:10.14229/jadc (2014).
  Google Scholar
• 53 Buhler J, Gietzen S, Reuter A et al. Selective uptake of cylindrical poly(2-oxazoline) brush-antidec205 antibody-ova antigen conjugates into dec-positive dendritic cells and subsequent T-cell activation. Chemistry 20(39), 12405–12410 (2014). •• Introduction of inert poly(2-oxaziline) brushes as vectors for targeted antigen delivery into CD8+ dendritic cells for cytotoxic T-cell responses via anti-DEC205 antibodies.
  Medline CASGoogle Scholar
• 54 Serra P, Santamaria P. Nanoparticle-based autoimmune disease therapy. Clin. Immunol. doi:10.1016/j.clim.2015.02.003 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 55 Maldonado RA, Lamothe RA, Ferrari JD et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl Acad. Sci. USA 112(2), E156–E165 (2015).
  Medline CASGoogle Scholar
• 56 Yeste A, Nadeau M, Burns EJ, Weiner HL, Quintana FJ. Nanoparticle-mediated codelivery of myelin antigen and a tolerogenic small molecule suppresses experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 109(28), 11270–11275 (2012).
  Medline CASGoogle Scholar
• 57 Becker J, Andersen M, Schrama D, Thor Straten P. Immune-suppressive properties of the tumor microenvironment. Cancer Immunol. Immunother. 62(7), 1137–1148 (2013).
  Medline CASGoogle Scholar
• 58 Domling A, Holak TA. Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 53(9), 2286–2288 (2014).
  MedlineGoogle Scholar
• 59 Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4⁺ CD25⁺ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 25(3), 207–217 (2002).
  Medline CASGoogle Scholar
• 60 Bopp T, Radsak M, Schmitt E, Schild H. New strategies for the manipulation of adaptive immune responses. Cancer Immunol. Immunother. 59(9), 1443–1448 (2010).
  Medline CASGoogle Scholar
• 61 Ulges A, Klein M, Reuter S et al. Protein kinase CK2 enables regulatory T cells to suppress excessive Th2 responses in vivo. Nat. Immunol. 16(3), 267–275 (2015).
  Medline CASGoogle Scholar
• 62 Martin F, Ladoire S, Mignot G, Apetoh L, Ghiringhelli F. Human FOXP3 and cancer. Oncogene 29(29), 4121–4129 (2010).
  Medline CASGoogle Scholar
• 63 Sun L, Wu J, Yi S. FOXP3 is critical for human natural CD4⁺CD25⁺ regulatory T cells to suppress alloimmune response. Transpl. Immunol. 26(2–3), 71–80 (2012).
  Medline CASGoogle Scholar
• 64 Ali H, Weigmann B, Neurath MF, Collnot EM, Windbergs M, Lehr CM. Budesonide loaded nanoparticles with ph-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. J. Control. Release 183, 167–177 (2014).
  Medline CASGoogle Scholar
• 65 Collnot EM, Ali H, Lehr CM. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J. Control. Release 161(2), 235–246 (2012).
  Medline CASGoogle Scholar
• 66 Schmidt C, Lautenschlaeger C, Collnot EM et al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J. Control. Release 165(2), 139–145 (2013).
  Medline CASGoogle Scholar
• 67 Lademann J, Richter H, Teichmann A et al. Nanoparticles–an efficient carrier for drug delivery into the hair follicles. Eur. J. Pharm. Biopharm. 66(2), 159–164 (2007).
  Medline CASGoogle Scholar
• 68 Bal SM, Ding Z, Van Riet E, Jiskoot W, Bouwstra JA. Advances in transcutaneous vaccine delivery: Do all ways lead to rome? J. Control. Release 148(3), 266–282 (2010).
  Medline CASGoogle Scholar
• 69 Mittal A, Raber AS, Schaefer UF et al. Non-invasive delivery of nanoparticles to hair follicles: a perspective for transcutaneous immunization. Vaccine 31(34), 3442–3451 (2013).
  Medline CASGoogle Scholar
• 70 Mittal A, Schulze K, Ebensen T et al. Inverse micellar sugar glass (imsg) nanoparticles for transfollicular vaccination. J. Control. Release 206, 140–152 (2015).
  Medline CASGoogle Scholar
• 71 Mittal A, Schulze K, Ebensen T et al. Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation. Nanomedicine 11(1), 147–154 (2015). •• Important and innovative publication showing the potential of transfollicular vaccination.
  Medline CASGoogle Scholar
• 72 Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Persp. 113(7), 823–839 (2005).
  Medline CASGoogle Scholar
• 73 Hittinger M, Juntke J, Kletting S, Schneider-Daum N, De Souza Carvalho C, Lehr CM. Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. Adv. Drug Deliv. Rev. 85, 44–56 (2014).
  MedlineGoogle Scholar
• 74 Ruge CA, Schaefer UF, Herrmann J et al. The interplay of lung surfactant proteins and lipids assimilates the macrophage clearance of nanoparticles. PLoS ONE 7(7), e40775 (2012).
  Medline CASGoogle Scholar
• 75 Schaefer J, Schulze C, Marxer EEJ et al. Atomic force microscopy and analytical ultracentrifugation for probing nanomaterial protein interactions. ACS Nano 6(6), 4603–4614 (2012).
  Medline CASGoogle Scholar
• 76 Schleh C, Kreyling WG, Lehr CM. Pulmonary surfactant is indispensable in order to simulate the in vivo situation. Part. Fibre Toxicol. 10, 6 (2013).
  MedlineGoogle Scholar
• 77 De Souza Carvalho C, Daum N, Lehr C-M. Carrier interactions with the biological barriers of the lung: advanced in vitro models and challenges for pulmonary drug delivery. Adv. Drug Deliv. Rev. 75(0), 129–140 (2014). •• Important review describing notably advanced in vitro model to study the lung delivery of particles.
  Medline CASGoogle Scholar
• 78 Lu C, Maurer CK, Kirsch B, Steinbach A, Hartmann RW. Overcoming the unexpected functional inversion of a PQSR antagonist in Pseudomonas aeruginosa: an in vivo potent antivirulence agent targeting pqs quorum sensing. Angew. Chem. Int. Ed. Engl. 53(4), 1109–1112 (2014). •• Important and recent paper showing the discovery of the first antivirulence compound that is potent in vivo and targets the virulence regulator PqsR of Pseudomonas aeruginosa: proof of concept for this novel antivirulence therapy.
  Medline CASGoogle Scholar
• 79 Nafee N, Husari A, Maurer CK et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J. Control. Release 192, 131–140 (2014). • Interesting paper describing solid lipid nanoparticles active against P. aeruginosa biofilm.
  Medline CASGoogle Scholar
• 80 Mahiny AJ, Dewerth A, Mays LE et al. In vivo genome editing using nuclease-encoding mrna corrects sp-b deficiency. Nat. Biotech. 33(6), 584–586 (2015).
  Medline CASGoogle Scholar
• 81 Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int. J. Antimicrob. Agents 43(6), 485–496 (2014). •• One of the first general reviews showing the potential of nanoparticles to treat intracellular infections.
  Medline CASGoogle Scholar
• 82 Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harbor Perspect. Biol. 2(5), a000414 (2010).
  MedlineGoogle Scholar
• 83 Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J. Control. Release 190, 607–623 (2014). •• Important review describing lipid and polymer nanoparticles for overcoming in vitro biofilm resistance: there is a need for more in vivo studies in this field.
  Medline CASGoogle Scholar
• 84 Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66(17), 2873–2896 (2009). • Complete and comprehensive review describing the different nanoparticle uptake mechanisms and the factors that can have an influence.
  Medline CASGoogle Scholar
• 85 Hao N, Li L, Zhang Q et al. The shape effect of pegylated mesoporous silica nanoparticles on cellular uptake pathway in hela cells. Microporous Mesoporous Mater. 162(0), 14–23 (2012).
  CASGoogle Scholar
• 86 Lepeltier E, Bourgaux C, Maksimenko A et al. Self-assembly of polyisoprenoyl gemcitabine conjugates: influence of supramolecular organization on their biological activity. Langmuir 30(22), 6348–6357 (2014). •• Recent study showing the link between the supramolecular structure of a nanoparticle and its cell internalization and the complexity to predict the uptake mechanism that can be different for the same particle according to the cell line studied.
  Medline CASGoogle Scholar
• 87 Zandi R, Reguera D, Bruinsma RF, Gelbart WM, Rudnick J. Origin of icosahedral symmetry in viruses. Proc. Natl Acad. Sci. USA 101(44), 15556–15560 (2004). • Important study where, by computer modeling, the importance of the icosahedral virus shape is discussed.
  Medline CASGoogle Scholar
• 88 Koren E, Apte A, Jani A, Torchilin VP. Multifunctional pegylated 2c5-immunoliposomes containing ph-sensitive bonds and tat peptide for enhanced tumor cell internalization and cytotoxicity. J. Control. Release 160(2), 264–273 (2012).
  Medline CASGoogle Scholar
• 89 Qian Z, Larochelle JR, Jiang B et al. Early endosomal escape of a cyclic cell-penetrating peptide allows effective cytosolic cargo delivery. Biochemistry 53(24), 4034–4046 (2014).
  Medline CASGoogle Scholar
• 90 Baio JE, Schach D, Fuchs AV et al. Reversible activation of pH-sensitive cell penetrating peptides attached to gold surfaces. Chem. Commun. (Camb.) 51(2), 273–275 (2015).
  MedlineGoogle Scholar
• 91 Huh AJ, Kwon YJ. “Nanoantibiotics”: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Control. Release 156(2), 128–145 (2011). • Comprehensive review about antimicrobial nanoparticles and antibiotic delivery systems as new tools to tackle the current challenges in treating infectious diseases.
  Medline CASGoogle Scholar
• 92 Jena P, Mohanty S, Mallick R, Jacob B, Sonawane A. Toxicity and antibacterial assessment of chitosan-coated silver nanoparticles on human pathogens and macrophage cells. Int. J. Nanomedicine 7, 1805–1818 (2012).
  Medline CASGoogle Scholar
• 93 Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano 6(5), 4279–4287 (2012). •• Very interesting publication showing an ingenious surface of nanoparticle charge switching, in order to shield nontarget interactions at pH 7.4 but bind avidly to bacteria in acidic area.
  Medline CASGoogle Scholar
• 94 Costanza F, Padhee S, Wu H et al. Investigation of antimicrobial peg-poly(amino acid)s. RSC Adv. 4(4), 2089–2095 (2014).
  CASGoogle Scholar
• 95 Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 22(2), 223–230 (2010).
  Medline CASGoogle Scholar
• 96 Irvine AS, Trinder PK, Laughton DL et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat. Biotechnol. 18(12), 1273–1278 (2000).
  Medline CASGoogle Scholar